Research & Education

Emerging Therapy Options in Immunotherapy for NSCLC

December 20, 2016 at 9:00PM EST - Recording Available



Sarah Goldberg, MD
Assistant Professor of Medicine
Yale School of Medicine and
Yale Cancer Center

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Name of Reviewer(s): 


Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 


Emerging Therapy Options in Immunotherapy for NSCLC

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, and/or faculty’s et.l. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Sarah Goldberg, MD

Supported/Contracted Research/Grant: Research grant from AstraZeneca

Program Chair: Ramaswamy Govindan, MD-

Speakers or Advisory Board , Honoraria and consulting with the following: BI, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, ARAID Pharmaceuticals, Astellas; Honoraruim with the following: Baxalta, Roche

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:

Immunotherapy is now a standard option for treatment of patients with non-small cell lung cancer and has been shown to improve survival compared to chemotherapy in a subset of patients.  This presentation will:

  • review the data behind the use of immunotherapy targeting the PD-1 axis in patients with lung cancer;
  • discuss the role of PD-L1 as a biomarker;
  • present examples of patients treated with these agents; 
  • discuss real-world challenges including toxicities that can arise with the use of the PD-1 and PD-L1 inhibitors.

After attending this program, participants will be able:

  • Identify the rationale behind using immunotherapy targeting the PD-1 axis in patients with non-small cell lung cancer;
  • Clarify the use of PD-L1 as a biomarker in practice;
  • Recognize and learn about managing toxicities of immunotherapy.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Goldberg via internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. 

In order to receive CME credit, attendees must fill out a program evaluation.

Financial/Commercial and Conflicts of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)


Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2016. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

Use the Time Zone Converter